Table 5.
List of additional drug modalities in the modified ITT population
| Other Treatments received during study n (%) | Steroid + Azithromycin (N = 116) | Azithromycin (N = 110) | Lopinavir/Ritonavir (N = 110) | Total (N = 336) | P-value |
|---|---|---|---|---|---|
| Oral steroid | 6 (5.17) | 11 (10.0) | 16 (14.6) | 33 (9.8) | 0.118 |
| Intravenous steroid | 8 (6.9) | 15 (13.6) | 6 (5.5) | 29 (8.6) | 0.032 |
| Steroid pulse therapy | 12 (10.3) | 10 (9.1) | 3 (2.7) | 25 (7.4) | 0.055 |
| Interferone | 1 (0.9) | 1 (0.9) | 0 (0) | 2 (0.6) | 0.578 |
| NSAID | 8 (6.9) | 10 (9.1) | 20 (18.2) | 38 (11.3) | 0.038 |
| Anticoagolant | 61 (52.6) | 63 (57.3) | 69 (62.7) | 193 (57.4) | 0.881 |
| Bronchodilator | 21 (18.1) | 24 (21.8) | 30 (27.3) | 75 (22.3) | 0.287 |
| Plasmapheresis | 4 (3.5) | 1 (0.9) | 3 (2.7) | 8 (2.4) | 0.386 |
| Favipiravir | 1 (0.9) | 0 (0) | 1 (0.9) | 2 (0.6) | 0.610 |
| Hyperimmune plasma | 4 (3.5) | 0 (0) | 2 (1.8) | 6 (1.8) | 0.141 |
| CinnoRA | 7 (6.0) | 6 (5.5) | 4 (3.6) | 17 (5.1) | 0.547 |
| Hemoperfiosion | 0 (0) | 1 (0.9) | 2 (1.8) | 3 (0.9) | 0.354 |
| Actemra | 0 (0) | 1 (0.9) | 3 (2.7) | 4 (1.2) | 0.163 |